Status:
UNKNOWN
Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma
Lead Sponsor:
Center Trials & Treatment Europe
Collaborating Sponsors:
Center Trials & Treatment
Conditions:
Non Small Cell Lung Cancer
Eligibility:
MALE
21-40 years
Phase:
PHASE1
Brief Summary
In non-small cell lung cancer and metastases in the pleural cavity, pathological effusion is formed. Currently, the most common and effective method of obliteration of the pleural cavity is pleurodes...
Detailed Description
The proposed procedure for dry pleurodesis consists of one stage. Talc is introduced into the pleural cavity in several ways: * Drainage - a tube is inserted into the pleural cavity through a punctu...
Eligibility Criteria
Inclusion
- Non-small cell lung cancer with positive mutation of EGFR verified
- Malignant pleural effusion
- Recurrent pleural effusion
- Complete lung expansion (\> 80%) after puncture emptying confirmed by chest radiography.
- Karnofsky index \> 50
- Agreed to participate in the study and sign an Informed Consent
Exclusion
- Radiotherapy not earlier than 3 months before the pleurodesis procedure
- Previous surgeries on the same hemitorace
- Thrombocytopenia or coagulation disorders
- Trapped lung syndrome
- Patients with estimated life expectancy \< 4-8 weeks
- Pleural or active systemic infection
Key Trial Info
Start Date :
March 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 21 2023
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03827070
Start Date
March 5 2019
End Date
July 21 2023
Last Update
April 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Contact
Tbilisi, Georgia, 0008